A Phase 1b, 12-Week, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of PF-06946860 In Patients with Non-Small Cell Lung Cancer and Cachexia

Administered By

Awarded By

Contributors

Start/End

  • August 13, 2020 - June 30, 2025